DrugCite
Search

INVANZ

Adverse Events
Drug Profile
Learn More
Reference
About Results
Comments

Invanz Adverse Events Reported to the FDA Over Time

How are Invanz adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Invanz, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Invanz is flagged as the suspect drug causing the adverse event.

Most Common Invanz Adverse Events Reported to the FDA

What are the most common Invanz adverse events reported to the FDA?

Convulsion
195 (6.03%)
Confusional State
97 (3%)
Hallucination
79 (2.44%)
Pyrexia
53 (1.64%)
Death
47 (1.45%)
No Therapeutic Response
43 (1.33%)
Nausea
36 (1.11%)
Delirium
35 (1.08%)
Diarrhoea
35 (1.08%)
Asthenia
34 (1.05%)
Drug Ineffective
33 (1.02%)
Show More Show More
Drug Interaction
32 (.99%)
Grand Mal Convulsion
32 (.99%)
Hallucination, Visual
30 (.93%)
Rash
30 (.93%)
Agitation
28 (.87%)
Vomiting
28 (.87%)
Muscular Weakness
26 (.8%)
Fall
25 (.77%)
Sepsis
25 (.77%)
Mental Status Changes
24 (.74%)
Status Epilepticus
23 (.71%)
Disorientation
22 (.68%)
Clostridial Infection
21 (.65%)
Coma
20 (.62%)
Epilepsy
20 (.62%)
Paraesthesia
20 (.62%)
Pneumonia
20 (.62%)
Adverse Event
19 (.59%)
Alanine Aminotransferase Increased
19 (.59%)
Chills
19 (.59%)
Myoclonus
19 (.59%)
Tremor
19 (.59%)
Aspartate Aminotransferase Increase...
18 (.56%)
Dizziness
18 (.56%)
Gait Disturbance
18 (.56%)
Urticaria
18 (.56%)
Chest Pain
17 (.53%)
Mental Impairment
17 (.53%)
Renal Failure Acute
17 (.53%)
Blood Creatinine Increased
16 (.49%)
Dysarthria
16 (.49%)
Thrombosis
16 (.49%)
Depressed Level Of Consciousness
15 (.46%)
Encephalopathy
15 (.46%)
Hypotension
15 (.46%)
Renal Failure
15 (.46%)
Respiratory Failure
15 (.46%)
Drug Level Decreased
14 (.43%)
Hypoglycaemia
14 (.43%)
Dyspnoea
13 (.4%)
Loss Of Consciousness
13 (.4%)
Pruritus
13 (.4%)
Somnolence
13 (.4%)
Cardiac Arrest
12 (.37%)
Pre-existing Disease
12 (.37%)
Abdominal Pain Upper
11 (.34%)
Agranulocytosis
11 (.34%)
Depressed Mood
11 (.34%)
Haematoma
11 (.34%)
Headache
11 (.34%)
Multi-organ Failure
11 (.34%)
Stevens-johnson Syndrome
11 (.34%)
Tachycardia
11 (.34%)
Abasia
10 (.31%)
Alopecia
10 (.31%)
Cholecystitis Acute
10 (.31%)
Cough
10 (.31%)
Haematochezia
10 (.31%)
Overdose
10 (.31%)
Psychotic Disorder
10 (.31%)
Renal Impairment
10 (.31%)
Thrombocytopenia
10 (.31%)
Transaminases Increased
10 (.31%)
Gamma-glutamyltransferase Increased
9 (.28%)
Hepatic Enzyme Increased
9 (.28%)
Injection Site Rash
9 (.28%)
Myocardial Infarction
9 (.28%)
Oedema Peripheral
9 (.28%)
Pain
9 (.28%)
Rash Maculo-papular
9 (.28%)
Restlessness
9 (.28%)
White Blood Cell Count Increased
9 (.28%)
Abdominal Pain
8 (.25%)
Anaemia
8 (.25%)
Anaphylactic Reaction
8 (.25%)
Blood Pressure Increased
8 (.25%)
Cerebral Atrophy
8 (.25%)
Hepatitis
8 (.25%)
Hospitalisation
8 (.25%)
Insomnia
8 (.25%)
Lethargy
8 (.25%)
Medication Error
8 (.25%)
Oedema
8 (.25%)
Osteomyelitis
8 (.25%)
Rash Generalised
8 (.25%)
Septic Shock
8 (.25%)
Skin Exfoliation
8 (.25%)
Urinary Tract Infection
8 (.25%)
Abnormal Behaviour
7 (.22%)
Blood Urea Increased
7 (.22%)

ExportShare/Embed GraphExport Export Data

This graph shows the top adverse events submitted to the FDA for Invanz, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Invanz is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Invanz

What are the most common Invanz adverse events reported to the FDA?

Show More Show More

ExportShare/Embed Graph Export Export Data

This graph shows the top categories of adverse events submitted to the FDA for Invanz, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Invanz is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Common Uses of Invanz According to Those Reporting Adverse Events

Why are people taking Invanz, according to those reporting adverse events to the FDA?

Infection
128
Urinary Tract Infection
67
Pneumonia
64
Osteomyelitis
47
Cellulitis
47
Prophylaxis
31
Show More Show More
Cholecystitis Acute
28
Sepsis
28
Product Used For Unknown Indication
26
Drug Use For Unknown Indication
24
Diabetic Foot Infection
22
Diverticulitis
21
Abdominal Infection
17
Bacterial Infection
15
Kidney Infection
13
Escherichia Infection
12
Appendicitis
11
Skin Ulcer
10
Klebsiella Infection
10
Peritonitis
10
Pneumonia Aspiration
10
Prostatitis
10
Staphylococcal Infection
10
Diabetic Foot
9
Cholecystitis
9
Infection Prophylaxis
9
Abscess
8
Pneumonia Bacterial
8
Osteitis
8
Streptococcal Infection
7
Abdominal Abscess
7
Skin Infection
7
Bacteraemia
6
Evidence Based Treatment
6
Abscess Limb
5
Pyelonephritis
5
Pyrexia
5
Lung Infection
5
Wound Infection
5
Respiratory Tract Infection
5
Cholangitis
5
Device Related Infection
5
Lower Respiratory Tract Infection
4
Soft Tissue Infection
4
Abdominal Sepsis
4
Arthritis Bacterial
4
Urinary Tract Infection Pseudomonal
4
Pelvic Abscess
4
Liver Abscess
4
Post Procedural Infection
4
Localised Infection
4

Drug Labels

LabelLabelerEffective
InvanzMerck Sharp & Dohme Corp.17-FEB-12

Invanz Case Reports

What Invanz safety concerns are being reported by doctors and researchers in the medical literature?

Powered by Google

About Results

This report contains aggregated drug side effects and adverse events for Invanz. The data has been pulled from the United States Food and Drug Administration's (US FDA) Adverse Event Reporting System (AERS), a database containing more than 4,000,000 adverse event reports.

DrugCite expands your query using the Unified Medical Language System (UMLS) to include generic drugs and primary active ingredients. While the core of DrugCite's advanced drug filtering algorithm is based on the industry standard UMLS, DrugCite's proprietary filtering system also includes dozens of additional steps to reconcile malformed drug names in the FDA's data.

DrugCite only counts a drug if the submitter of the adverse event indicates that the drug is suspected to have caused the adverse event.

Depending on how the data is aggregated, different counts may occur. When someone submits an adverse event to the FDA, the submitter can attribute multiple adverse events to one or more drugs. For example, an individual taking Paxil could submit the adverse events "anxiety" and "suicidal ideation" for the same individual safety report (ISR). This means when DrugCite aggregates by adverse event, two distinct adverse events are counted in the adverse event graph; once for "anxiety" and again for "suicidal ideation". However, when DrugCite aggregates by individual safety reports irrespective of the details of the adverse events contained within the safety report, the report is only counted once.

Comments

Share your experience with Invanz.